In this episode of Meeting Mic, we bring you Healio’s top headlines from ACR Convergence 2023. 

Eric Roberts, PhD, MPH, compares the uptake of biosimilar infliximab among patients with Medicare, Medicaid and private insurance in the U.S. :19 

Shivani Garg, MD, MS, discusses how a therapeutic range of hydroxychloroquine blood levels may reduce the odds of high lupus disease activity. 2:09 

Kaleb Michaud, PhD, discusses patients with rheumatoid arthritis who reported having long COVID in the past year demonstrating “many symptoms” of long COVID prior to initial infection. 12:00 

Leonard H. Calabrese, DO, highlights the “year in review”, issues in vasculitis, and cautionary notes on CAR T cell therapies. 14:18  

Jill Buyon, MD, discusses how pregnant patients with very low anti-Ro antibody titers of less than 1,000 units per mL have minimal-to-no risk for fetal atrioventricular block. 15:15 

Read the full coverage here: 

https://www.healio.com/news/rheumatology/20231113/medicare-fails-to-keep-up-with-medicaid-private-market-on-infliximab-biosimilar-uptake 

https://www.healio.com/news/rheumatology/20231120/stay-within-hydroxychloroquine-therapeutic-threshold-to-reduce-active-lupus-flare-risk  

https://www.healio.com/news/rheumatology/20231116/patients-with-rheumatoid-arthritis-report-many-symptoms-of-long-covid-prior-to-infection  

@LCalabreseDO 

https://www.healio.com/news/rheumatology/20231113/pregnant-patients-with-low-antiro-titers-have-little-to-no-risk-for-fetal-heart-block 

Disclosures: 

Roberts, Garg, Michaud and Calabrese report no relevant financial disclosures. Buyon reports financial disclosures with Bristol-Myers Squibb, GlaxoSmithKline and Related Sciences.